Current partner codePEPTIDESDE
PeptideStat
Menu

Vendors

Compare pricesVendor directoryVendor reviewsDiscount codesLab tests & COAs

Research

ResearchDatabaseClinical trials

Tools

All calculatorsReconstitutionAccumulationUnit converterPeptide chemistry
NCT05485818·Phase 2·INTERVENTIONAL

Safety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.Infarction

Thymosin Beta-4OtherCompleted

Status

Completed

Phase

Phase 2

Enrollment

62

Locations

1

Results

Not posted

Publications

6

Study summary

What the protocol is testing.

A multicenter randomized double-blind placebo parallel control design was used in this study.60 subjects eligible for inclusion will be randomly assigned to either a low-dose (0.25ug/kg) medium-dose (0.5ug/kg) high-dose (2.0ug/kg) experimental drug group or a control group (placebo) at a ratio of 1:1:1:1.After randomization, subjects received the experimental drug or placebo once a day, intravenously, on day 2 to 7, 12 hours and 4 hours after PCI.Ninety days after PCI were observed.

Full detailed description

Subjects underwent cardiovascular magnetic resonance imaging (CMR) on the 90th day after PCI, which was used to evaluate the myocardial salvage index myocardial infarction area, microvascular occlusion area, left ventricular ejection fraction (LVEF), left ventricular end-systolic volume (LVESV), and left ventricular end-diastolic volume (LVEDV).Echocardiography was performed on the 5th and the 90th day after PCI to evaluate the left indoor diameter (LV) and left atrial diameter (LA) of LVEF. Physical examination routine blood coagulation function was performed on the 30th and 90th day after PCI in the screening period (pre-screening results were acceptable);Electrocardiogram (ECG) was performed on the 30th and the 90th day after PCI on the 2nd day after the first administration;During the screening period (results before screening are acceptable), vital signs should be measured from day 1 to day 7 after PCI (during each dose, vital signs should be measured twice on day 7, including before and after administration), on day 30 and day 90;Blood biochemical examinations were performed from day 2 to day 4, day 7, day 30, and day 90 after PCI before the first administration;Creatine kinase isoenzyme (CK-MB) hypersensitive troponin I(HS-CTNI) or troponin I(cTnI) and amino-terminal B-type natriuretic peptide precursor (NT-probNP) or B-type natriuretic peptide (BNP) were detected on day 2, day 3, day 4 and day 7 after PCI before the first administration.Tumor markers were detected and immunogenicity blood samples were collected 30 days after PCI before the first administration.Routine urinalysis was performed 90 days after PCI before the first administration;Adverse drug events and cardiovascular events were continuously recorded during the trial.

Interventions

Treatment arms and agents.

DRUG

Low Dose

12±4 hours after PCI: 0.25 ug/kg Recombinant Human Thymosin β4 （intravenous injection），Day2-Day7 after PCI：0.25 ug/kg Recombinant Human Thymosin β4 （intravenous injection）

DRUG

Middle Dose

12±4 hours after PCI: 0.5 ug/kg Recombinant Human Thymosin β4 （intravenous injection），Day2-Day7 after PCI：0.5 ug/kg Recombinant Human Thymosin β4 （intravenous injection）

DRUG

High Dose

12±4 hours after PCI: 2.0 ug/kg Recombinant Human Thymosin β4 （intravenous injection），Day2-Day7 after PCI：2.0 ug/kg Recombinant Human Thymosin β4 （intravenous injection）

OTHER

Placebo

15 subjects will be randomly assigned to the placebo for 7 days

Timeline

From registration to results.

  1. First posted

    Aug 3, 2022

  2. Study start

    Nov 23, 2020

  3. Primary completion

    Sep 30, 2021

  4. Study completion

    Nov 18, 2021

  5. Results posted

    Not reported

  6. Registry updated

    Aug 3, 2022

Outcomes

What the study measures.

Primary outcomes

Change of myocardial infarction area on Day 5 and day 90 after PCI

Time frame · Day 5、Day 90

Change of myocardial infarction area on Day 5 and day 90 after PCI. Myocardial infarction area day 5 and day 90 after PCI，and the change on day 90 compared to day 5. Myocardial infarction size was evaluated by late gadolinium enhanced cardiac magnetic resonance (LGE-CMR) imaging.

Secondary outcomes

Change of myocardial salvage index on Day 5 and day 90 after PCI

Time frame · Day 5、Day 90

Myocardial salvage index day 5 and day 90 after PCI，and the change on day 90 compared to day 5. Myocardial salvage index (%) defifined as: (area at risk-infarct size)/ area at risk\*100% measured by CMR. Higher scores mean a better outcome.

Change of microvascular obstruction area on Day 5 and day 90 after PCI

Time frame · Day 5、Day 90

Area of microvascular obstruction day 5 and day 90 after PCI，and the change on day 90 compared to day 5. Microvascular obstruction is one of the risk factors affecting the prognosis of AMI patients. The occurrence of MVO is related to the release of cytotoxic factors caused by distal microvascular embolization and reperfusion injury. Studies have shown a significantly increased risk of heart failure, adverse cardiovascular events, and death. late gadolinium enhancement (LGE) was performed to identify areas of microvascular obstruction (MVO), the typical MVO is the low signal area in the high signal area of infarction.

Change of LA on Day 5 and day 90 after PCI

Time frame · Day 5、Day 90

Change of left atrium (LA) on Day 5 and day 90 after PCI, The data of LA after PCI were measured by CMR at Day 5 and day 90, and calculate changes in data day 90 and day 5.

Changeof LV on Day 5 and day 90 after PCI

Time frame · Day 5、Day 90

Change of left ventricle (LV) on Day 5 and day 90 after PCI, Day 5 and day 90 LV after PCIwere measured by CMR at Day 5 and day 90, and calculate changes in data day 90 and day 5.

Change of LVEF on Day 5 and day 90 after PCI

Time frame · Day 5、Day 90

Change of Left Ventricular Ejection Fractions (LVEF) on Day 5 and day 90 after PCI, Day 5 and day 90 LVEF after PCIwere measured by CMR at Day 5 and day 90, and calculate changes in data day 90 and day 5.

Change of LVESV on Day 5 and day 90 after PCI

Time frame · Day 5、Day 90

Change of Left Ventricular end-systolic volume (LVESV) on Day 5 and day 90 after PCI, Day 5 and day 90 LVESV after PCI were measured by CMR at Day 5 and day 90, and calculate changes in data day 90 and day 5.

Change of LVEDV on Day 5 and day 90 after PCI

Time frame · Day 5、Day 90

Change of Left Ventricular end-diastolic volume (LVEDV) on Day 5 and day 90 after PCI, Day 5 and day 90 LVEDV after PCI were measured by CMR at Day 5 and day 90, and calculate changes in data day 90 and day 5.

Number of participants with treatment-related adverse events as assessed by NCI-CTCAE v5.0

Time frame · Day0、Day1、Day2、Day3、Day4、Day5、Day6、Day7、Day30、Day90

Number of participants with adverse events (AE), treatment-related adverse events, abnormal vital signs, abnormal physical examination findings, abnormal laboratory test results, abnormal electrocardiograms

Incidence of anti-drug antibody (ADA)

Time frame · Day 0、Day 30

Blood samples were collected before administration and 30 days after PCI to evaluate the immunogenicity of NL005

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
75 Years
Sex
ALL
Healthy volunteers
No

Inclusion Criteria: 1. The subject or its legal representative will voluntarily participate in the study and sign the informed consent; 2. Age 18 and 75, regardless of gender; 3. STEMI patients with left anterior descending branch single-artery middle occlusion (TIMI grading 0\~1, see Appendix 1 for TIMI grading) and receiving PCI; 4. No obvious collateral of coronary artery (Rentrop grade 0\~1,Rentrop grade see Appendix 2); 5. Chest pain occurred for 6 hours and 12 hours before PCI; 6. TIMI grade 3 after PCI; 7. All subjects (male and female) must agree to use appropriate contraceptive methods (hormonal or barrier contraceptive methods, abstinence) during the study period and up to 6 months after the last administration, and women of childbearing age must test negative for pregnancy before administration. Exclusion Criteria: 1. Patients who have a history of myocardial infarction or have received coronary artery acute thrombolytic interventional therapy with bypass surgery; 2. patients who received thrombolytic therapy after onset; 3. patients who were clearly diagnosed as acute heart failure (Killip grade II,Killip classification in annex 3); 4. Severe arrhythmia that cannot be corrected; 5. Aortic dissection or suspected presence; 6. Severe liver and kidney dysfunction or severe depletion, etc; 7. major surgical history or hemorrhagic stroke in half a year; 8. Has or has a history of malignancy; 9. Systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg in patients with hypertension after active antihypertensive treatment; 10. Clinically, he had a significant history of allergy, especially to mannitol, drugs, protein preparations and biological products; 11. Screening of patients who participated in other clinical studies within the first 3 months; 12. Failure to perform CMR test: such as claustrophobia, renal failure (eGFR \< 30ml/min); 13. Other conditions not considered suitable for inclusion by the researcher.

Study locations

1 registered sites.

China. Showing up to 24 locations stored in the fast local snapshot.

Fuwai Hospital, Chinese Academy of Medical Sciences

Beijing, China

Publications

Results and literature.

PMID 20937304 ↗Limana F, Capogrossi MC, Germani A. The epicardium in cardiac repair: from the stem cell view. Pharmacol Ther. 2011 Jan;129(1):82-96. doi: 10.1016/j.pharmthera.2010.09.002. Epub 2010 Oct 19.PMID 21952932 ↗Wrigley BJ, Lip GY, Shantsila E. The role of monocytes and inflammation in the pathophysiology of heart failure. Eur J Heart Fail. 2011 Nov;13(11):1161-71. doi: 10.1093/eurjhf/hfr122. Epub 2011 Sep 27.PMID 18537603 ↗Gutierrez SH, Kuri MR, del Castillo ER. Cardiac role of the transcription factor NF-kappaB. Cardiovasc Hematol Disord Drug Targets. 2008 Jun;8(2):153-60. doi: 10.2174/187152908784533702.PMID 21527742 ↗Gordon JW, Shaw JA, Kirshenbaum LA. Multiple facets of NF-kappaB in the heart: to be or not to NF-kappaB. Circ Res. 2011 Apr 29;108(9):1122-32. doi: 10.1161/CIRCRESAHA.110.226928.PMID 23050819 ↗Srivastava D, Ieda M, Fu J, Qian L. Cardiac repair with thymosin beta4 and cardiac reprogramming factors. Ann N Y Acad Sci. 2012 Oct;1270:66-72. doi: 10.1111/j.1749-6632.2012.06696.x.PMID 22236126 ↗Dube KN, Bollini S, Smart N, Riley PR. Thymosin beta4 protein therapy for cardiac repair. Curr Pharm Des. 2012;18(6):799-806. doi: 10.2174/138161212799277699.

Primary links

Continue at the source.

ClinicalTrials.gov ↗Search PubMed ↗Search FDA ↗Search EMA ↗

Related trials

More studies on Thymosin Beta-4.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.

TrialsThymosin Beta-4 trial dashboard →DatabaseThymosin Beta-4 database entry →ResearchThymosin Beta-4 research guide →